Clinical Predictive Circulating Peptides in Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy

Journal of Cellular Physiology

Volumn 230, Issue 8, 2015, Pages 1822-1828

  Crotti, Sara ^a,b   Enzo, Maria Vittoria ^c   Bedin, Chiara ^b,c   Pucciarelli, Salvatore ^c   Maretto, Isacco ^c   Del Bianco, Paola ^d   Traldi, Pietro ^e   Tasciotti, Ennio ^f   Ferrari, Mauro ^f   Rizzolio, Flavio ^a   Toffoli, Giuseppe ^a   Giordano, Antonio ^g   Nitti, Donato ^c   Agostini, Marco ^b,c,f  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Istituto Ricerca Pediatrica   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e CNR   (Italy)

^f HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^g Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRADYKININ; CLUSTERIN; SILICON DIOXIDE; PEPTIDE; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PEPTIDE ANALYSIS; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOM FOREST; RECEIVER OPERATING CHARACTERISTIC; RECTUM CANCER; ADENOCARCINOMA; ADJUVANT THERAPY; BLOOD; CHEMORADIOTHERAPY; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; LAB ON A CHIP; MASS SPECTROMETRY; MIDDLE AGED; NANOTECHNOLOGY; PROCEDURES; RECTAL NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CHEMORADIOTHERAPY; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LAB-ON-A-CHIP DEVICES; MALE; MIDDLE AGED; NANOTECHNOLOGY; NEOADJUVANT THERAPY; PEPTIDES; RECTAL NEOPLASMS; ROC CURVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 84928394287     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24894     Document Type: Article

References (39)

1. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC . 2006. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114-1123.
2. Bouamrani A, Hu Y, Tasciotti E, Li L, Chiappini C, Liu XW, Ferrari M . 2010. Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics 10:496-505.
3. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Jarl NA, Crane CH . 2007. Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 109:1750-1755.
4. Diaz-Uriarte R . 2007. GeneSrF and varSelRF: A web-based tool and R package for gene selection and classification using random forest. Bmc Bioinformatics 8: Article-ID number: 328.
5. Dowling P, Clarke C, Hennessy K, Torralbo-Lopez B, Ballot J, Crown J, Kiernan I, O'Byrne KJ, Kennedy MJ, Lynch V, Clynes M . 2012. Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. Int J Cancer 131:911-923.
6. Falkner JA, Falkner JW, Andrews PC. 2006. ProteomeCommons.org JAF: Reference information and tools for proteomics. Bioinformatics 22:632-633.
7. Gianazza E, Chinello C, Mainini V, Cazzaniga M, Squeo V, Albo G, Signorini S, Di Pierro SS, Ferrero S, Nicolardi S, van der Burgt YE, Deelder AM, Magni F . 2012. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors. J Proteomics 76 Spec No. 125-140.
8. Helgason HH, Engwegen JYMN, Zapatka M, Vincent A, Cats A, Boot H, Beijnen JH, Schellens JHM . 2010. Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry. Oncol Rep 24:57-64.
9. Hu Y, Bouamrani A, Tasciotti E, Li L, Liu XW, Ferrari M . 2010. Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. Acs Nano 4:439-451.
10. Hu Y, Gopal A, Lin K, Peng Y, Tasciotti E, Zhang XJ, Ferrari M . 2011. Microfluidic enrichment of small proteins from complex biological mixture on nanoporous silica chip. Biomicrofluidics 5. Article-ID number is: 013410.
11. Karpova MA, Moshkovskii SA, Toropygin IY, Archakov AI . 2010. Cancer-specific MALDI-TOF profiles of blood serum and plasma: Biological meaning and perspectives. J Proteomics 73:537-551.
12. Klokov D, Criswell T, Leskov KS, Araki S, Mayo L, Boothman DA . 2004. IR-inducible clusterin gene expression: A protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects. Mutat Res 568:97-110.
13. Kuremsky JG, Tepper JE, McLeod HL . 2009. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74:673-688.
14. Li Y, Chen T, Kuklina AS, Bernard P, Esteva FJ, Shen H, Ferrari M, Hu Y . 2014. Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer. Clin Chem 60:233-242.
15. Li Z, Lu H, Yang J, Zeng X, Zhao L, Li H, Liao Q, Peng S, Zhou M, Wu M, Xiang J, Wang Y, Li G . 2013. Analysis of the raw serum peptidomic pattern in glioma patients. Clin Chim Acta 425:221-226.
16. Liang T, Wang N, Li W, Li A, Wang J, Cui J, Liu N, Li Y, Li L, Yang G, Du Z, Li D, He K, Wang G . 2010. Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics 10:90-98.
17. Liaw A, Wiener M . 2002. Classification and Regression by randomForest. R News 2:18-22.
18. Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Petricoin EF, 3rd, Liotta LA, Patton WF, Whiteley GR, Rosenblatt K, Gurnani P, Nandi A, Neill S, Cullen S, O'Gorman M, Sarracino D, Lynch C, Johnson A, McKenzie W, Fishman D . 2007. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. Clin Chem 53:1067-1074.
19. Maher SG, McDowell DT, Collins BC, Muldoon C, Gallagher WM, Reynolds JV . 2011. Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann Surg 254:809-817.
20. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henryamar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier JM, Bonvalot S, Gignoux M . 1994. Pathological assessment of tumor-regression after preoperative chemoradiotherapy of esophageal-carcinoma. Cancer 73:2680-2686.
21. Markiewski MM, Lambris JD . 2009. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol 30:286-292.
22. Mazzarelli P, Pucci S, Spagnoli LG . 2009. CLU and colon cancer. The dual face of CLU: From normal to malignant phenotype. Adv Cancer Res 105:45-61.
23. Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara PF, McGrath P, Marks GM . 2000. Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. Int J Radiat Oncol Biol Phys 48:1075-1080.
24. Novak K . 2006. Biomarkers: Taking out the trash. Nat Rev Cancer 6:92-92.
25. Petricoin EF, Belluco C, Araujo RP, Liotta LA . 2006. The blood peptidome: A higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer 6:961-967.
26. Prado GN, Taylor L, Zhou X, Ricupero D, Mierke DF, Polgar P . 2002. Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. J Cell Physiol 193:275-286.
27. Pucci S, Bonanno E, Sesti F, Mazzarelli P, Mauriello A, Ricci F, Zoccai GB, Rulli F, Galata G, Spagnoli LG . 2009. Clusterin in stool: A new biomarker for colon cancer screening. Am J Gastroenterol 104:2807-2815.
28. Roh MS, Colangelo LH, O'Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N . 2009. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124-5130.
29. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT . 2010. Cancer and the complement cascade. Mol Cancer Res 8:1453-1465.
30. Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K . 2005. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47:141-146.
31. Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, Reichrath J . 2006. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 13:12-19.
32. Shen Y, Tolic N, Liu T, Zhao R, Petritis BO, Gritsenko MA, Camp DG, Moore RJ, Purvine SO, Esteva FJ, Smith RD . 2010. Blood peptidome-degradome profile of breast cancer. PLoS ONE 5:e13133.
33. Smith FM, Gallagher WM, Fox E, Stephens RB, Rexhepaj E, Petricoin EF, Liotta L, Kennedy MJ, Reynolds JV . 2007. Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg 245:259-266.
34. Song W, Wang N, Li W, Wang G, Hu J, He K, Li Y, Meng Y, Chen N, Wang S, Hu L, Xu B, Wang J, Li A, Cui J . 2013. Serum peptidomic profiling identifies a minimal residual disease detection and prognostic biomarker for patients with acute leukemia. Oncol Lett 6:1453-1460.
35. Strohalm M, Hassman M, Kosata B, Kodicek M . 2008. MMass data miner: An open source alternative for mass spectrometric data analysis. Rapid Commun Mass Sp 22:905-908.
36. van Winden AW, van den Broek I, Gast MC, Engwegen JY, Sparidans RW, van Dulken EJ, Depla AC, Cats A, Schellens JH, Peeters PH, Beijnen JH, van Gils CH . 2010. Serum degradome markers for the detection of breast cancer. J Proteome Res 9:3781-3788.
37. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P . 2006. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116:271-284.
38. Voortman J, Pham TV, Knol JC, Giaccone G, Jimenez CR . 2009. Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling. Proteome Sci 7. Article-ID number is: 34.
39. Yi J, O'Mullan P, Craft D, Foucher A, Finocchio T, Veltre D, Kim C, Gelfand CA . 2006. Inhibition of intrinsic proteolytic activity moderates preanalytic variability and stabilizes the human plasma proteome. Mol Cell Proteomics 5:S275-S275.